MADRID, Feb. 24, 2011 /PRNewswire/ -- Zeltia Group's net revenues totaled 153.5 million euro in 2010 (approximately 211.4 million USD*), 24.4 percent more than in 2009 (123.4 million euro, or approximately 169.9 million USD). This performance is primarily attributable to a 70 percent increase in Yondelis® sales.
Net sales in the Biopharmaceutical business amounted to 79.4 million euro (approximately 109.3 million USD) in 2010 (51.1 million euro, or approximately 70.3 million USD in 2009), of which 72.1 million (approximately 99.3 million USD) correspond to Yondelis® (43.8 million euro, or approximately 60.3 million USD in 2009).
The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro, or approximately 100.8 million USD in 2010, compared with 71.1 million euro, or approximately 97.9 million USD in 2009).
EBITDA improved by 74 percent in 2010 to -3.9 million euro (approximately -5.3 million USD) (-15.3 million euro or approximately -21.0 million USD in 2009).
Net income attributable to the parent company rose 71 percent with respect to 2009.
Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.
This note is also available on the Zeltia web site: www.zeltia.com.
* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3773.
Copyright©2010 PR Newswire.
All rights reserved